The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Brain Imaging of Nicotinic Receptors in Alzheimer's Disease
Open accessAbstract
Neuronal nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion channels which are widely distributed in the human brain. Several lines of evidence suggest that two major subtypes (α4β2 and α7) of nAChRs play an important role in the pathophysiology of Alzheimer's disease (AD). Postmortem studies demonstrated alterations in the density of these subtypes of nAChRs in the brain of patients with AD. Currently, nAChRs are one of the most attractive therapeutic targets for AD. Therefore, several researchers have made an effort to develop novel radioligands that can be used to study quantitatively the distribution of these two subtypes in the human brain with positron emission tomography (PET) and single-photon emission computed tomography (SPECT). In this paper, we discuss the current topics on in vivo imaging of two subtypes of nAChRs in the brain of patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“It has been shown that the accumulation of Aβ precedes other pathological changes and causes neurodegeneration or neuronal death in vitro and in vivo [20, 21].”
BackgroundBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Evidence for striatal dopamine release during a video game
Koepp, M. J., Gunn, R. N., Lawrence, A. D., Cunningham, V. J., Dagher, A., Jones, T., Brooks, D. J., Bench, C. J., & Grasby, P. M. (1998) · Nature · doi:10.1038/30498 · Cited by 1,279 · cited 1×
“Further studies in which dopamine release during physiologic activation can be assessed, as reduced raclopride binding, are of great interest and of importance: Functional stimulation by playing a video game (51) may elicit dopamine release, which can also be observed during repetitive transcortical magnetic stimulati…”
BackgroundEvans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · cited 1×
“Several reports indicated that it is affecting almost 1 in 10 individuals over the age of 65 [1], and as life expectancy increases, over 37 million people suffer with AD, and it is projected to quadruple by 2050 [2].”
BackgroundNicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Strafella, A. P., Paus, T., Barrett, J., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-j0003.2001 · Cited by 1,058
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Wang, G.-J., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2004) · Journal of Addictive Diseases · doi:10.1300/j069v23n03_04 · Cited by 502 · cited 1×
“The dopamine system is also activated by placebo infusion due to the expectation of improvement of extrapyramidal symptoms and pain (53,54) and as a reward system in substance abuse and addiction (55) as well as in obesity (56).”
BackgroundRole of dopamine in drug reinforcement and addiction in humans: results from imaging studies
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00008 · Cited by 398 · cited 1×
“The dopamine system is also activated by placebo infusion due to the expectation of improvement of extrapyramidal symptoms and pain (53,54) and as a reward system in substance abuse and addiction (55) as well as in obesity (56).”
BackgroundD'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390 · cited 1×
“For example, levels of α7 nAChR protein were reduced by 36% in the hippocampus of AD patients [15], but α7 nAChR mRNA expression is increased by 65% [18].”
BackgroundPaylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A., & Orr-Urtreger, A. (1998) · Learning & Memory · doi:10.1101/lm.5.4.302 · Cited by 298 · cited 1×
“PET studies of [11C]CHIBA-1001 in patients with AD are currently underway with [11C]Pittsburgh compound D ([11C]PiB)-PET and [18F]fluorodeoxyglucose ([18F]FDG)-PET.”
MethodIyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., & Irie, T. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09124-6 · Cited by 259
In Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder
Pearlson, G. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180057008 · Cited by 235 · cited 1×
“This controversy has not been entirely resolved, but the finding with spiperone seems not to be specific for schizophrenia (44).”
BackgroundImpaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211 · cited 1×
“This reduction was limited to brain regions where intraneuronal Aβ42 accumulation occurred [73].”
BackgroundHernandez, C. M., Kayed, R., Zheng, H., Sweatt, J. D., & Dineley, K. T. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5038-09.2010 · Cited by 204 · cited 2×
“The cognitive deficits seen in APP transgenic mice worsen when α7 nAChR is absent at the same time [84].”
BackgroundResultBrendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190
The placebo effect in neurological disorders
de la Fuente-Fernández, R., Schulzer, M., & Stoessl, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00038-8 · Cited by 187
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179 · cited 1×
“The improved therapeutic efficacy of these atypical neuroleptics probably derives from a more moderate D2 receptor blockade (hence, decreased extrapyramidal side effects) and increased prefrontal D1 and NMDA-receptor transmission (50).”
BackgroundLaminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., & Nordberg, A. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00117-x · Cited by 175
5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors
Mukhin, A. G., Gündisch, D., Horti, A. G., Koren, A. O., Tamagnan, G., Kimes, A. S., Chambers, J., Vaupel, D. B., King, S. L., Picciotto, M. R., et al. (2000) · Molecular Pharmacology · doi:10.1124/mol.57.3.642 · Cited by 173
Cosgrove, K. P., Batis, J., Bois, F., Maciejewski, P. K., Esterlis, I., Kloczynski, T., Stiklus, S., Krishnan-Sarin, S., O’Malley, S., Perry, E., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.41 · Cited by 165
D1 dopamine receptor binding in mood disorders measured by positron emission tomography
Suhara, T., Nakayama, K., Inoue, O., Fukuda, H., Shimizu, M., Mori, A., & Tateno, Y. (1992) · Psychopharmacology · doi:10.1007/bf02253582 · Cited by 163 · cited 1×
“Studies with these radioligands indicated a significant decrease in D1 receptor density in the striatum and frontal cortex of patients with bipolar affective disorders and in the prefrontal cortex of patients with schizophrenia (22,23).”
BackgroundHoyle, E., Genn, R. F., Fernandes, C., & Stolerman, I. P. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0549-2 · Cited by 161
Farías, G. G., Vallés, A. S., Colombres, M., Godoy, J. A., Toledo, E. M., Lukas, R. J., Barrantes, F. J., & Inestrosa, N. C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3934-06.2007 · Cited by 108
Whitehouse, P. J., & Kalaria, R. N. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00002 · Cited by 79
Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT
Mitsis, E. M., Cosgrove, K. P., Staley, J. K., Bois, F., Frohlich, E. B., Tamagnan, G. D., Estok, K. M., Seibyl, J. P., & van Dyck, C. H. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.008 · Cited by 65
Cited by
Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline
Ballinger, E. C., Ananth, M., Talmage, D. A., & Role, L. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.006 · Cited by 730
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Pathophysiology of primary burning mouth syndrome
Jääskeläinen, S. K. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.07.054 · Cited by 281
Waters, F., Chiu, V., Atkinson, A., & Blom, J. D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00303 · Cited by 165
Nicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Metadata
- Authors
- Wu, J., Ishikawa, M., Zhang, J., & Hashimoto, K.
- Venue
- International Journal of Alzheimer's Disease
- Publisher
- Wiley
- Published
- 2010
- Volume
- 2010
- Issue
- 2
- Pages
- 1-11
- ISSN
- 2090-0252 (ISSN-L)
- OpenAlex
- W2134568558
- Cited by
- 205
- References
- 28
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.